Novavax Reports More Delays for Its Covid-19 Vaccine

“I don’t see a lot going well for them at this point,” said Rob Smith, the managing director of Capital Alpha Partners, an investment research firm.The company’s delay is unlikely to affect wealthy countries like the United States, which is flush with vaccines from Moderna, Pfizer-BioNTech and Johnson & Johnson.But it is likely to have significant repercussions for the rest of the world, given that just last week, Novavax finalized a deal with Gavi, a public-private global vaccine partnership, to supply 1.1 billion doses of its shot to low- and middle-income countries. Novavax has struck other deals with countries like South Korea, Japan and Australia, and has set up agreements with eight production plants around the world.

window.onload = function () {
const target = document.querySelector(‘#covid-signup-module’);
const options = {
channel: ‘covid-tracker’,
region: ‘inline’,
productCode: ‘PUCV’,
channelName: ‘Covid Tracker’,

const config = {

#covid-signup-module {
margin-left: 20px;
margin-right: 20px;
width: calc(100% – 40px);
max-width: 600px;

@media (min-width: 600px) {
#covid-signup-module {
margin-left: auto;
margin-right: auto;
width: 100%;

In January, the company estimated that it would hit its full production capacity of 150 million doses a month by the middle of this year, a prediction it later revised after facing a shortage of supplies like filters and the giant single-use bags that are used in vaccine manufacturing. On Monday, the company delayed its estimate again, saying it expected to reach production of 100 million doses a month by the end of the third quarter, and to make 150 million a month by the fourth quarter.One of its major manufacturing partners, the Serum Institute in India, has faced its own production and geopolitical challenges. A fire at the facility earlier this year reduced its capacity, and in April, Serum’s chief executive, Adar Poonawalla, called out the United States for restricting access to raw vaccine ingredients. And though Novavax’s deal with Serum is intended to supply the rest of the world through its arrangement with Gavi, the Indian government has banned exports of vaccines from the country as it struggles with a deadly second wave of Covid-19.

Leave a Reply

Your email address will not be published. Required fields are marked *